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Abstract

Öz

Objective: The purpose of this study was to analyze the difference in
duration of anticoagulation and dose of warfarin required to reach a
therapeutic international normalized ratio [(INR) of 2 to 3] in patients
with hypercoagulable conditions as compared to controls. To our
knowledge, this study is the first in the literature to delineate such
a difference.

Amaç: Bu çalışmanın amacı kontrollerle karşılaştırıldığında
hiperkoagülabilite durumları olan hastalarda terapötik uluslararası
düzeltme oranında (INR) 2 ile 3 aralığına ulaşmak için gerekli warfarin
doz ve antikoagülan süresindeki farklılığı analiz etmektir. Bildiğimiz
kadarıyla; bu farklılığı tarifleyen literatürdeki ilk çalışmadır.

Materials and Methods: A retrospective chart review was performed
in a tertiary care hospital. The total study population was 622.
Cases (n=125) were patients with a diagnosis of a hypercoagulable
syndrome who developed venous thromboembolism. Controls (n=497)
were patients with a diagnosis of venous thromboembolism in the
absence of a hypercoagulable syndrome and were matched for age,
sex, and race.

Gereç ve Yöntemler: Retrospektif dosya taraması 3. basamak
hastanede yapıldı. Toplam çalışmaya alınan hasta sayısı 622 idi. Venöz
tromboembolizmi olan bu hastalardan 125’inin hiperkoagülabilite
sendromu olup yaş, cins ve etnik kökeni aynı 497 kontrol hastasında
hiperkoagülabilite sendromu yoktu.

Results: The total dose of warfarin required to reach therapeutic INR
in cases was higher (50.7±17.6 mg) as compared to controls (41.2±17.7
mg). The total number of days required to reach therapeutic INR in
cases was 8.9±3.5 days as compared to controls (6.8±2.9 days). Both
of these differences were statistically significant (p<0.001).

Bulgular: Hastalarda terapötik INR’ye ulaşmak için gerekli total
warfarin dozu (50,7±17,6 mg) kontrollerin dozu (41,2±17,7 mg) ile
karşılaştırıldığında yüksekti. Terapötik INR’ye ulaşmak için gerekli
total gün sayısı hastalarda 8,9±3,5 gün olup kontrollerde 6,8±2,9 gün
idi. Her iki karşılaştırmada da istatistiksel farklılık anlamlı bulundu
(p<0,001).

Conclusion: Patients with hypercoagulable conditions require
approximately 10 mg of additional total warfarin dose and also
require, on average, 2 extra days to reach therapeutic INR as compared
to controls.

Sonuç: Hiperkoagülabilite durumları olan hastalarda terapötik INR’ye
ulaşmak için kontrollere göre yaklaşık 10 mg ek total warfarin dozu ve
ortalama 2 ek gün gereklidir.

Keywords: International normalized ratio, Warfarin, Hypercoagulable
conditions, Venous thromboembolism
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Introduction
It has been well documented that both acquired and
hypercoagulable conditions play an important role in
thrombophilia development. Studies suggest that important
genetic factors that have notable significance include factor
V Leiden mutation, prothrombin gene mutation, deficiency
of protein S or protein C, antithrombin III deficiency, and
hyperhomocysteinemia. Acquired hypercoagulability factors
include non-modifiable factors, such as age and antiphospholipid
antibodies, and modifiable factors, such as pregnancy, oral
contraceptive and hormone replacement therapy, recent travel,
and obesity, as well other factors such as malignancy, recent
surgery, trauma, and prolonged immobility [1].
Once a patient develops venous thromboembolism (VTE), the
main mode of treatment has been warfarin, with recent advent
of newer medications such as rivaroxaban [2]. Warfarin still
remains one of the most commonly used medications for VTE in
the United States. Previously there have been a few studies that
have investigated warfarin dosing in specific hypercoagulable
conditions, such as antiphospholipid antibodies and highversus low-intensity warfarin efficacy in recurrent deep vein
thrombosis (DVT) prevention [3]. However, it is not known if a
difference exists in the total dose and time of warfarin therapy
necessary to reach a therapeutic international normalized ratio
(INR) in patients with hypercoagulable conditions. The goal of
this study was to determine the difference in the time and dose
of warfarin required to reach therapeutic INR (i.e. INR of 2 to
3) in patients with hypercoagulable conditions as compared to
controls.

Materials and Methods
The study was approved by our institutional review board. A
retrospective chart review was performed for patients seen in our
tertiary care facility from January 2002 to December 2012. The
inclusion criteria for cases were patients with hypercoagulable
conditions, which included patients with factor V Leiden
mutation, prothrombin gene mutation, protein S or protein
C deficiency, antithrombin III deficiency, dysfibrinogenemia,
and antiphospholipid antibodies who developed unprovoked
VTE (DVT, pulmonary embolism, or both). The diagnostic tests
used were venous duplex for DVT and computed tomography
angiogram or ventilation/perfusion lung scan for pulmonary
embolism. Controls were age-, sex-, and race-matched patients
who developed VTE but did not have a hypercoagulable
syndrome. Confounding factors were assessed in both cases and
controls and included end-stage renal disease, malignancies,
recent surgery (within 1 month of development of VTE), and
oral contraceptive use. Therapeutic INR was defined as an INR of
2-3 on 2 consecutive blood draws separated by a 24-h duration.
All subjects received an initial 5-mg loading dose of warfarin
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and all of them received heparin at the time of diagnosis of VTE
(bridging therapy). The total dose of warfarin required to reach
a therapeutic INR and the number of days required to reach a
therapeutic INR were analyzed.
Statistical analysis with a primary aim of comparing cases to
controls was performed. Data were described using standard
descriptive statistics, i.e. counts, percentages, means, and
standard deviations. Crude (unadjusted) odds ratios were
obtained from univariate logistic regression models. All variables
with a univariate p-value of <0.2 were placed in a multivariable
logistic regression and stepwise selection with stay criteria
of p≤0.05 were used to arrive at a final model. Statistical
significance was set at p<0.05 and all analyses were performed
using SAS 9.4 (SAS Institute Inc., Cary, NC, USA).

Results
A total of 622 patients were analyzed in this study. Of these,
125 were cases and 497 were controls. The mean age at the time
of diagnosis of VTE in both cases and controls was 53 years. In
all, 58% of the patients were female. The male to female ratios
for both the cases and controls were roughly the same. The
most common race was Caucasian (59%), followed by African
American (32%); other races constituted 9% of the total study
population. Among the patient population, 39% developed a
DVT, 42% developed a pulmonary embolism, and 18% developed
both a DVT and a pulmonary embolism.
The total number of days required to reach therapeutic INR was
8.9±3.5 days in cases, whereas in controls it was 6.8±2.9 days.
The difference was found to be statistically significant (p<0.001).
The total dose of warfarin required to reach therapeutic INR
was 50.7±17.6 mg in cases as compared to 41.2±17.7 mg in
controls. The difference remained statistically significant after
multivariate regression analysis (p<0.001).
A multivariable model was built starting with all variables with
a univariate p-value of <0.2. Stepwise selection was then used
to arrive at the final model given in Table 1. We found that
every 1-day increase in the number of days to therapeutic INR
was associated with 19% increased odds of being a case, and
every 1-unit increase in warfarin dose to therapeutic INR was
associated with 1% increased odds of being a case.

Discussion
For the last 60 years, warfarin has been the mainstay of
management of thromboembolism in a variety of both
hereditary and acquired conditions [4]. Even with its narrow
therapeutic index, meticulous monitoring, dire adverse effects,
and interactions with an array of foods, drugs, and herbs,
warfarin is still the most widely used oral anticoagulant in
North America with over 25 million prescriptions in the United
States in 2010 [4,5].
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Warfarin acts by interfering with the enzyme vitamin K epoxide
reductase, which modulates the gamma carboxylation of
procoagulant factors II, VII, IX, and X and anticoagulant proteins
C, S, and Z [6]. Because of the latter action, warfarin has the
potential of exerting a transient procoagulant effect early in
therapy. To counter that, heparin ‘bridging’ is recommended for
a minimum of 5 days and until the INR is 2.0 or above for at least
24 h [7]. As the antithrombotic effect of warfarin necessitates
the inhibition of factor II, which has a very long half-life (60-72
h) as compared to other factors (6-24 h), it takes approximately
6 days for warfarin to exert its full efficacy even though the
earliest changes in INR can be seen after 24 to 36 h [8,9,10,11].
The average number of days to achieve therapeutic INR after
starting warfarin is reported to be 5-6 days [12].
Selection of an appropriate dose for warfarin initiation
is challenging and controversial because of interpersonal
variability in its pharmacokinetic and pharmacodynamic
parameters. Kovacs et al. found that patients who were initiated

with 10 mg of warfarin achieved therapeutic INR 1.4 days earlier
than those who received 5 mg [13]. One study concluded that
initiation with 5 mg of warfarin was associated with 5.6 days of
bridging with low-molecular-weight heparin [14]. The American
College of Chest Physicians recommends initiation with 10 mg
in patients healthy enough to be treated as outpatients, with
dose modifications done as per the INR after 2 days [7]. From a
practical point of view, adjusting the warfarin dose to achieve
and maintain therapeutic INR is a challenging task that we
face regularly during our day-to-day clinical encounters. A
myriad of factors lead to this commonly observed interpatient
variation in the warfarin dose requirement and number of days
required to achieve the therapeutic INR. Our study compared
these 2 variables in patients with and without hypercoagulable
conditions. We found that patients with hypercoagulable
conditions on average require higher doses and more days
to achieve the target INR as compared to those without any
hypercoagulable conditions. To our knowledge, this study is one
of the first in the literature to delineate such a difference.

Table 1. Patient characteristics along with univariate and multivariate analysis.
Variable

Response

Cases (n=125)

Controls
(n=497)

Univariate
Analysis
OR (95% CI)

p-value

Multivariate
Analysis
OR (95% CI)

p-value

Age

Mean ± SD

60.4±15.0

60.5±16.0

1.00 (0.98, 1.01)

0.939

Sex

Male
Female

55 (44%)
70 (56%)

207 (42%)
290 (58%)

1.10 (0.74, 1.64)

0.634

Race

Caucasian
African American
Other1

72 (58%)
38 (30%)
15 (12%)

293 (59%)
160 (32%)
44 (9%)

1.04 (0.67, 1.60)
1.44 (0.72, 2.85)

0.556

VTE

DVT
PE
Both

44 (35%)
53 (42%)
28 (22%)

201 (40%)
211 (42%)
85 (17%)

0.66 (0.39, 1.14)
0.76 (0.45, 1.29)

0.326

Age at time of
VTE

Mean ± SD

53.0±14.9

53.5±15.0

0.99 (0.98, 1.01)

0.747

Cancer

No
Yes

122 (98%)
3 (2%)

450 (91%)
47 (9%)

0.24 (0.07, 0.77)

0.009

0.26 (0.08, 0.87)

0.029

End-stage renal No
disease
Yes

122 (98%)
3 (2%)

489 (98%)
8 (2%)

1.50 (0.39, 5.75)

0.549

Surgery

No
Yes

118 (94%)
7 (6%)

371 (75%)
126 (25%)

0.18 (0.08, 0.38)

<0.001

0.13 (0.06, 0.31)

<0.001

Antibiotics

No
Yes

102 (82%)
23 (18%)

407 (82%)
90 (18%)

1.02 (0.61, 1.69)

0.940

Oral
contraceptive
pills

No
Yes

122 (98%)
3 (2%)

478 (96%)
19 (4%)

0.62 (0.18, 2.12)

0.441

Total days to
Mean ± SD
therapeutic INR

8.9±3.5 (5.4 to 12.4)

6.8±2.9
(3.9 to 9.7)

1.22 (1.15, 1.29)

<0.001

1.19 (1.10, 1.28)

<0.001

Total dose to
Mean ± SD
therapeutic INR

50.7±17.6 (33.1 to 68.3)

41.2±17.7
(23.5 to 58.9)

1.03 (1.02, 1.04)

<0.001

1.01 (1.00, 1.03)

0.034

1All

other races except Caucasian and African American, SD: Standard deviation, VTE: venous thromboembolism, INR: international normalized ratio, CI: confidence interval, OR: odds
ratio, DVT: deep vein thrombosis.
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As described earlier, other factors might also affect the variables
under study, which could have been potential confounders in
our study. The elderly and females require a smaller weekly
dose of warfarin than their counterparts. Even though there
are no convincing data, it is generally preferred that the elderly
be started on a low-dose warfarin regimen because of the
exaggeration of anticoagulation response in this age group [15].
One of the strongest and statistically significant patient-specific
factors that can influence the warfarin dose requirement is the
concomitant use of drugs that affect cytochrome P450 (17.2 mg
additional dosage of warfarin per week) [16]. From antibiotics
to anticonvulsants, ginger to ginseng, and spinach to spices,
a tiring list of drugs, herbs, and foods is reported to interact
with warfarin by multiple mechanisms, which can involve its
absorption, bioavailability, metabolism, and excretion. Recent
surgery was also assessed as a variable in this study. It should be
noted that surgeries are generally considered to be transiently
hypercoagulable states. Surgeries involving lower extremities
(such as hip/knee replacement) carry the highest risk of VTE and
should be managed carefully in patients with hypercoagulable
states.
Even though not recommended for general testing, genetic
mutations can lead to variations in the dosage requirement of
warfarin among different patients, which ultimately affects
the number of days required to achieve the therapeutic INR.
Polymorphism in the VKORC1 gene, which codes for the target
enzyme for warfarin, results in 2 haplotypes: A, which makes
the patient sensitive to smaller doses, and B, which necessitates
administration of higher doses to achieve and maintain the same
range of INR. The Asp36Tyr missense mutation in VKORC1, found
in 15% of the Ethiopian population in one study, was strongly
associated with a warfarin requirement of >70 mg/week. On the
other hand, CYP2C9 (and less commonly CYP1A1, CYPCA1, and
CYP3A4), which metabolizes the more potent enantiomer of the
warfarin molecule, has been found to have 2 relatively common
variant forms with reduced activity (CYP2CP*2 and CYP2C9*3).
Patients with these variants have less rapid clearance of warfarin,
thus requiring lower dosage administrations [17]. In one study,
VKORC1 was significantly associated with the time required to
achieve the first therapeutic INR while CYP2C9 predicted the
time to reach an INR above 4, which predisposes the patient to
hemorrhagic complications [18,19].
Gene polymorphisms are found to be more common in
African Americans than Asians and Caucasians, which affects
the number of days and the dose needed to achieve the first
target INR. Other patient-specific factors that can affect the
variables under study include body mass index/body surface
area (especially height), poor compliance, comorbid conditions,
and true warfarin resistance, which is a quite rare occurrence
(0.01%) [19].
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The major limitation of this study is that it was a single-center,
retrospective study and the results might not be applicable to the
general population. Moreover, our ‘cases’ group was relatively
small, likely secondary to the rarity of the above-mentioned
hypercoagulable conditions. However, to compensate for this
relatively small sample size, we used a large ‘control’ group to
increase the power of the study. Every effort was made during
data collection to avoid bias as much as possible.

Conclusion
In summary, this study lays the foundation of a novel idea
of comparing warfarin dosage and the time required to
achieve therapeutic INR in patients with and without known
hypercoagulability conditions. The likely mechanism of the
observed difference is inherent thrombogenic potential in
hypercoagulable states with more natural resistance towards
anticoagulation. With a few confounders playing a role, this
proposition needs further consolidation with large-scale trials
that might help us in predicting the initial dose to start with
in patients with and without a procoagulant condition. The
observed effect can, in another way, be studied retrospectively
to understand the difference in the pathophysiology of the
thromboembolism in these 2 populations, which may explain
the etiological aspects of the results noticed.
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